Curanex Pharmaceuticals (NASDAQ:CURX) Releases Quarterly Earnings Results

Curanex Pharmaceuticals (NASDAQ:CURX) issued its quarterly earnings results on Friday. The company reported ($0.12) EPS for the quarter, FiscalAI reports.

Curanex Pharmaceuticals Price Performance

Shares of Curanex Pharmaceuticals stock traded down $0.00 during trading on Friday, reaching $0.22. 162,245 shares of the company traded hands, compared to its average volume of 106,872. Curanex Pharmaceuticals has a 1-year low of $0.18 and a 1-year high of $9.18. The company has a 50 day moving average price of $0.24 and a 200-day moving average price of $0.33. The firm has a market capitalization of $6.17 million and a PE ratio of -0.81.

Institutional Investors Weigh In On Curanex Pharmaceuticals

A hedge fund recently bought a new position in Curanex Pharmaceuticals stock. Citadel Advisors LLC acquired a new stake in shares of Curanex Pharmaceuticals Inc (NASDAQ:CURX) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 64,067 shares of the company’s stock, valued at approximately $46,000.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Curanex Pharmaceuticals in a research report on Wednesday, July 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

About Curanex Pharmaceuticals

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.